Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1996 1
1997 1
1998 2
1999 5
2000 3
2001 5
2002 6
2003 9
2004 10
2005 14
2006 13
2007 16
2008 11
2009 17
2010 9
2011 12
2012 14
2013 10
2014 12
2015 17
2016 14
2017 17
2018 10
2019 13
2020 8
2021 12
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Preface.
Nardo L, Lara PN Jr. Nardo L, et al. Among authors: lara pn jr. Curr Probl Cancer. 2023 Apr;47(2):100971. doi: 10.1016/j.currproblcancer.2023.100971. Epub 2023 Jun 8. Curr Probl Cancer. 2023. PMID: 37330401 No abstract available.
Metabolic reprogramming in clear cell renal cell carcinoma.
Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH. Wettersten HI, et al. Among authors: lara pn jr. Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Nat Rev Nephrol. 2017. PMID: 28480903 Review.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Quigley DA, et al. Among authors: lara pn jr. Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Cell. 2018. PMID: 30033370 Free PMC article.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. Pal SK, et al. Among authors: lara pn jr. Lancet. 2021 Feb 20;397(10275):695-703. doi: 10.1016/S0140-6736(21)00152-5. Epub 2021 Feb 13. Lancet. 2021. PMID: 33592176 Free PMC article. Clinical Trial.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Ryan CW, et al. Among authors: lara pn jr. Lancet. 2023 Sep 23;402(10407):1043-1051. doi: 10.1016/S0140-6736(23)00913-3. Epub 2023 Jul 28. Lancet. 2023. PMID: 37524096 Clinical Trial.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Among authors: lara pn jr. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Free PMC article. Clinical Trial.
Editorial Comment.
Dall'Era M, Lara PN Jr. Dall'Era M, et al. Among authors: lara pn jr. J Urol. 2018 Nov;200(5):1003. doi: 10.1016/j.juro.2018.06.071. Epub 2018 Jul 19. J Urol. 2018. PMID: 30030973 No abstract available.
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN Jr, Thompson IM Jr, Agarwal N. Sayegh N, et al. Among authors: lara pn jr. JAMA Netw Open. 2023 Aug 1;6(8):e2326546. doi: 10.1001/jamanetworkopen.2023.26546. JAMA Netw Open. 2023. PMID: 37526936 Free PMC article. Clinical Trial.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Kim JW, et al. Among authors: lara pn jr. J Clin Oncol. 2023 Feb 1;41(4):871-880. doi: 10.1200/JCO.21.02947. Epub 2022 Oct 18. J Clin Oncol. 2023. PMID: 36256912 Free PMC article. Clinical Trial.
255 results